Multiple studies have demonstrated that PD-L1 expression in tumor cells serves as an independent predictive biomarker for both prognosis and therapeutic efficacy, making it the most widely adopted biomarker for optimizing patient selection (4–7). Here, CD274 is linked to neoplasm.